Beacon developing saliva-based cancer tests under agreement with Centocor.
This article was originally published in The Gray Sheet
Executive Summary
BEACON DIAGNOSTICS SALIVA-BASED GASTROINTESTINAL CANCER TEST 510(k) is slated for submission to FDA in early 1998, the company says. The GI kit is the first product expected to come to market under an exclusive worldwide licensing agreement between Beacon and Centocor covering tumor detection technology.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.